Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Share-based Compensation for 10 consecutive years, with $37.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 6.45% to $37.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $153.0 million, a 3.16% decrease, with the full-year FY2025 number at $153.0 million, down 3.16% from a year prior.
  • Share-based Compensation was $37.5 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $37.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $41.6 million in Q3 2024 to a low of $24.3 million in Q1 2021.
  • A 5-year average of $34.1 million and a median of $35.3 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: soared 33.53% in 2022, then dropped 10.97% in 2025.
  • Ultragenyx Pharmaceutical's Share-based Compensation stood at $26.8 million in 2021, then grew by 9.31% to $29.3 million in 2022, then grew by 14.21% to $33.5 million in 2023, then increased by 19.74% to $40.1 million in 2024, then decreased by 6.45% to $37.5 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Share-based Compensation are $37.5 million (Q4 2025), $37.0 million (Q3 2025), and $38.5 million (Q2 2025).